Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

OSE Immunotherapeutics - Filing #5980970

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	—	—	—	—	54 027 EUR	—	—	—	—	—	51 576 EUR	—	—	—
Current assets	—	—	—	—	69 932 EUR	—	—	—	—	—	30 478 EUR	—	—	—
Non-current liabilities	—	—	—	—	39 927 EUR	—	—	—	—	—	40 280 EUR	—	—	—
Current liabilities	—	—	—	—	20 221 EUR	—	—	—	—	—	18 799 EUR	—	—	—
Profit (loss)	37 445 EUR	—	—	—	—	—	37 445 EUR	—	23 003 EUR	—	—	—	23 003 EUR	—
Other comprehensive income	20,000 EUR	—	—	—	—	—	—	—	86,000 EUR	—	—	—	—	—
Comprehensive income	37 425 EUR	- EUR	- EUR	- EUR	—	15,000 EUR	37 410 EUR	- EUR	23 089 EUR	- EUR	—	- EUR	23 012 EUR	77,000 EUR